Total Payments
$695,329
2024 Payments
$51,862
Companies
23
Transactions
309
Medicare Patients
216
Medicare Billing
$36,855
Payment Breakdown by Category
Consulting$335,490 (48.2%)
Other$145,898 (21.0%)
Research$129,204 (18.6%)
Travel$75,570 (10.9%)
Food & Beverage$9,167 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $335,490 | 72 | 48.2% |
| Unspecified | $129,204 | 8 | 18.6% |
| Honoraria | $111,178 | 13 | 16.0% |
| Travel and Lodging | $75,570 | 80 | 10.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,720 | 15 | 5.0% |
| Food and Beverage | $9,167 | 121 | 1.3% |
Payments by Type
General
$566,125
301 transactions
Research
$129,204
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| H. Lundbeck A S | $188,969 | 31 | $0 (2023) |
| Biogen, Inc. | $89,695 | 27 | $0 (2021) |
| Eisai Inc. | $84,311 | 65 | $0 (2024) |
| Novo Nordisk AS | $65,924 | 19 | $0 (2024) |
| Genentech, Inc. | $63,323 | 5 | $0 (2023) |
| Novo Nordisk Inc | $42,331 | 21 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $31,568 | 19 | $0 (2022) |
| Grifols Shared Services North America, Inc. | $31,194 | 19 | $0 (2020) |
| Genentech USA, Inc. | $23,518 | 14 | $0 (2021) |
| Lundbeck LLC | $21,774 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,862 | 49 | Novo Nordisk AS ($12,685) |
| 2023 | $193,448 | 64 | H. Lundbeck A S ($77,711) |
| 2022 | $57,277 | 32 | EISAI INC. ($14,001) |
| 2021 | $95,574 | 21 | Biogen, Inc. ($59,809) |
| 2020 | $83,217 | 28 | Biogen, Inc. ($24,945) |
| 2019 | $68,740 | 60 | Eisai Inc. ($23,375) |
| 2018 | $93,716 | 23 | H. Lundbeck A S ($71,740) |
| 2017 | $51,495 | 32 | H. Lundbeck A S ($25,194) |
All Payment Transactions
309 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Lundbeck LLC | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $7,800.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Lundbeck LLC | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $148.45 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $86.91 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $596.96 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $270.45 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $202.27 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $160.20 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.93 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $791.96 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $169.86 | General |
| Category: Neurology | ||||||
| 11/02/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| 11/02/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $4,889.33 | General |
| 11/02/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $225.16 | General |
| 11/02/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $70.35 | General |
| 10/19/2024 | Lundbeck LLC | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $221.89 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | In-kind items and services | $68.19 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | In-kind items and services | $45.45 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | In-kind items and services | $32.10 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT) | H. Lundbeck A S | $56,870 | 1 |
| NN6535-4725 | Novo Nordisk AS | $10,427 | 3 |
| NN6353-4730 | Novo Nordisk AS | $3,500 | 1 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $1,759 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 72 | 268 | $38,920 | $12,179 |
| 2022 | 3 | 33 | 159 | $18,780 | $5,459 |
| 2021 | 4 | 50 | 169 | $25,778 | $8,710 |
| 2020 | 4 | 61 | 123 | $33,074 | $10,507 |
Total Patients
216
Total Services
719
Medicare Billing
$36,855
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 36 | $12,168 | $4,678 | 38.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 19 | 157 | $13,816 | $3,894 | 28.2% |
| 96116 | Exam of neurobehavioral status, first hour | Office | 2023 | 18 | 37 | $9,250 | $2,624 | 28.4% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 19 | 38 | $3,686 | $981.54 | 26.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 11 | 103 | $9,064 | $2,638 | 29.1% |
| 96116 | Exam of neurobehavioral status, first hour | Office | 2022 | 11 | 28 | $7,000 | $2,079 | 29.7% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2022 | 11 | 28 | $2,716 | $741.52 | 27.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 28 | $9,464 | $3,867 | 40.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 13 | 98 | $8,624 | $2,515 | 29.2% |
| 96116 | Neurobehavioral status examination by qualified health care professional with interpretation and report, first 60 minutes | Office | 2021 | 13 | 23 | $5,750 | $1,757 | 30.6% |
| 96138 | Psychological or neuropsychological test administration and scoring by technician, first 30 minutes | Office | 2021 | 11 | 20 | $1,940 | $570.00 | 29.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 17 | 35 | $11,830 | $3,850 | 32.5% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 17 | 36 | $11,916 | $3,742 | 31.4% |
| 96116 | Neurobehavioral status examination by qualified health care professional with interpretation and report, first 60 minutes | Office | 2020 | 15 | 28 | $7,000 | $2,201 | 31.4% |
| 96138 | Psychological or neuropsychological test administration and scoring by technician, first 30 minutes | Office | 2020 | 12 | 24 | $2,328 | $714.96 | 30.7% |
About Alireza Atri, MD PHD
Alireza Atri, MD PHD is a Neurological Surgery healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1326038506.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Alireza Atri, MD PHD has received a total of $695,329 in payments from pharmaceutical and medical device companies, with $51,862 received in 2024. These payments were reported across 309 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($335,490).
As a Medicare-enrolled provider, Atri has provided services to 216 Medicare beneficiaries, totaling 719 services with total Medicare billing of $36,855. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurological Surgery
- Location Boston, MA
- Active Since 10/27/2005
- Last Updated 11/09/2012
- Taxonomy Code 207T00000X
- Entity Type Individual
- NPI Number 1326038506
Products in Payments
- REXULTI (Drug) $59,183
- Idalopirdine (Drug) $56,870
- Leqembi (Drug) $29,508
- NUPLAZID (Drug) $27,328
- Flebogamma DIF (Biological) $25,592
- EBIXA (Drug) $20,533
- ADUHELM (Biological) $12,632
- Non-Covered Product (Drug) $7,281
- RYBELSUS (Drug) $6,500
- Albutein (Biological) $6,427
- DISEASE EDUCATION (Drug) $4,240
- Rybelsus (Drug) $3,927
- NAMENDA (Drug) $1,220
- None (Drug) $116.78
- NEURACEQ (Drug) $93.34
- AMYVID (Drug) $17.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurological Surgery Doctors in Boston
Simcha Weller, M.d, M.D
Neurological Surgery — Payments: $1.2M
Neurological Surgery $1.2M
John Chi, Md, MD
Neurological Surgery — Payments: $289,008
Neurological Surgery $289,008
Dr. Philipp Taussky, Md, MD
Neurological Surgery — Payments: $288,839
Neurological Surgery $288,839
Dr. Robert Richardson, Md, Phd, MD, PHD
Neurological Surgery — Payments: $187,182
Neurological Surgery $187,182
Brendon Boot, Mbbs, MBBS
Neurological Surgery — Payments: $149,482
Neurological Surgery $149,482
Dr. Christopher Ogilvy, Md, MD
Neurological Surgery — Payments: $128,549
Neurological Surgery $128,549